Therapy Market Research Reports & Industry Analysis

... Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

Asian Cryotherapy Units Market to reach USD XXX billion by 2025. Asian Cryotherapy Units Market valued approximately USD XXX billion in 2016 is ... Target Audience of the Asian Cryotherapy Units Market in Market Study: Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture ...

... HER2 MESO EGFRvII Others Regional CAR-T Cell Therapy Market & Forecast North America Europe Asia Pacific Latin America Middle East Africa Global – CAR T Cell Therapy Clinical Trials/Study CD19 CD20 GD2 ...

... drug stability, which boost its demand in the market. The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and ... 6.9% from 2018 to 2025. The factors that propel the PEGylated protein therapeutics market growth include high prevalence of chronic diseases, such as cancer ...

... the growth in the stroke diagnostics and therapeutics market in Asia. Some of the key players diagnostics and therapeutics market include are Siemens ... and Daiichi Sankyo. Types Covered: Diagnostics Therapeutics Applications Covered: Haemorrhagic Stroke Ischemic Stroke Regions Covered: North America US Canada ...

... releases. The Barth Syndrome (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Barth Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

The global women’s health therapeutics market size is expected to reach USD 210.9 billion by 2025, according to a new ... commercialization and approval of products, and investment by market players Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva ...

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) development landscape Develop and design ...

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development ...

... is the 6th edition report on Proton Therapy Market by iGATE RESEARCH. The report titled “Proton Therapy Market Outlook, Actual & Potential Market, Actual and Potential Candidate for Proton Therapy, List of Proton Therapy Centers, Start of Treatment ...

... releases. The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... The report reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK ...

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape Develop and design in-licensing ...

... . The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development ...

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018 This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS ...

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway ... . In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on: Drug ...

... damage, and urinary tract infections (UTIs). The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, ... global benign prostatic hyperplasia therapeutics market is segmented into therapeutic class, therapy, and region. On the basis of therapeutic class, the market is ...

... . The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... releases. The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

... . The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... . The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape Develop and design ...

Competitor Analysis: PD-1 and PD-L1 ... specific R&D pipelines of PD-1 and PD-L1 checkpoint inhibitors. Competitor projects are listed in a tabular format providing information ... to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...

High-intensity focused ultrasound (HIFU) is a precise medical procedure, which applies high-intensity focused ultrasound energy to locally heat and destroy damaged or diseased tissue through ablation. In this therapy, ultrasound beams are focused on diseased ...

Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018 This Competitive Intelligence report analyzes the competitive field of CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors ...

... releases. The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... releases. The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

... releases. The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape Develop and design ...

... releases. The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... releases. The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

... reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development ...

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape Develop and ...

... Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... , Inc., and Others. This report segments the global Parkinsons disease therapeutics market as follows: Global Parkinsons Disease Therapeutics Market: Drug Class Segment Analysis Levodopa Combination Dopamine Agonists ...

... less successful against solid tumors. This report „TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & ... acquisition prices and financing rounds. Download Sample Pages: TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders ...

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, ... 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary ...

... releases. The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

... releases. The Premenstrual Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... (Clostridium difficile Associated Disease) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under ...

... . The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape Develop and design in-licensing and ...

... Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... segments the global monoclonal antibody therapeutics market as follows: Global Monoclonal Antibody Therapeutics Market: Application Segment Analysis Cancer Autoimmune Diseases Infection Hematological Diseases Others Global Monoclonal Antibody Therapeutics Market: Source Segment ...

... for these patients. In this report we discuss the recently approved therapies for CMV infections, other drugs and vaccines in the pipeline ...

... potential. Kuick Research Report on the Global cell therapy market provides a detailed insight into the current scenario of the cell therapy market worldwide. Key data like pricing of cell therapy products, cost analysis of cell therapy ...

This report analyzes the worldwide markets for Hot and Cold Therapy Packs in US$ by the following Product Segments: Cold Packs, Hot Packs, Moist Therapy Packs, and Localized Heating/Cooling Pads. The ...